<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371518">
  <stage>Registered</stage>
  <submitdate>20/09/2016</submitdate>
  <approvaldate>22/09/2016</approvaldate>
  <actrnumber>ACTRN12616001326482</actrnumber>
  <trial_identification>
    <studytitle>Vitamin B12 Blood Level Absorption Study in Healthy Adult Volunteers.</studytitle>
    <scientifictitle>Vitamin B12 Blood Level Absorption Study in Healthy Adult Volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vitamin B12 Deficiency </healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To Evaluate the Absorption Efficacy Characteristics and Further Safety Over a 6-hour period of Vitamin B12 [1000 mcg administered as ONE dose orally] from SIX preparations to Healthy Participants. ORAL delivery, ONE preparation per participant/day, for six days. Each of the six preparations will be administered to each participant in the same order across six consecutive days. Clinical Trial coordinator to oversee dose administered. 
1) FitBioceuticals 2 sprays= 1000 mcg
2) Blackmores 10 tablets= 1000 mcg
3) Vitamin Shoppe 1mL= 1000 mcg
4) Bioceuticals enzymatic dissolvable 1 tablet= 1000 mcg
5) Jarrow 1 capsule= 1000 mcg
6) InMed Technologies LLC 0.3mL = 1000 mcg</interventions>
    <comparator>Allocation: Non-Randomised; Self Control; Active Control; Endpoint Classification: Efficacy of Absorption / Safety Trial; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Absorption Characteristics of Vitamin B12 Preparations; Overall Study Duration: 12 Weeks to Complete recruitment and study. Sequential allocation to each preparation once the target sample size has been met. Comparing six preparations of Vitamin B12, with each participant acting as their own control. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absorption Characteristics: Plasma concentration of Vitamin B12</outcome>
      <timepoint>Blood draws at t-0 (baseline), 60, 180, 360 minutes. 4 time points/day over six consecutive days.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety. Clinical Trial Coordinator to monitor participants and any adverse effects. Any adverse effects will be documented in the individuals Case Report Form. Side effects may include (but not limited to); itchy skin, headache and nausea. </outcome>
      <timepoint>Trial Coordinator will monitor each participant and adverse effects from baseline to 6 hours post dose.  </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Participants &gt; 18 years of age at time of entry on study 
2) No evidence or documented history of chronic disease
3) Cognitive ability to understand informed consent process and to give informed consent to the experimental treatment
4) Caucasian Ethnicity </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any clinically relevant abnormal findings which, in the opinion of the investigators / clinicians, may put the participant at risk of adverse events because of participation in the clinical trial including:
1) Previous history of abnormal blood results i.e. FBE, U and E Liver Function Tests and vital signs
2) Use of vitamin or mineral supplements 1 week before the study and/or known adverse side effects to supplements
3) Use of pharmaceutical drugs (prescribed or over-the-counter)
4) Female participants who are lactating or pregnant
5) The current use of any nicotine products including:
i) nicotine patches/gum ii) tobacco smoking
6) History or alcohol or substance abuse including the use of any illicit drugs
7) Presence of chronic/acute illnesses including hypertension, high cholesterol, diabetes, obesity, irritable bowel syndrome, inflammatory bowel disease, coeliac disease
8) Any psychiatric disorders by history or examination that would prevent completion of the study or result in possible adverse events for the participant [suicide thoughts or euthanasia requests]
9) Vegetarianism </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>15/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/07/2015</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>58</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>28/02/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medlab Clinical </primarysponsorname>
    <primarysponsoraddress>66 McCauley Street, Alexandria, NSW, 2015</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medlab Clinical </fundingname>
      <fundingaddress>66 McCauley Street, Alexandria, NSW, 2015</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>There is significant interest from researchers, general practitioners and the public re: the administration of Vitamin B12 supplements for health maintenance or disease treatments. The aim of this study is to evaluate the absorption characteristics of a selected group of Australian and U.S MARKETED OVER THE COUNTER (OTC) VITAMIN B12 PRODUCTS. As such this study purposes to evaluate the absorption characteristics of these products. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Institue of Integrative Medicine</ethicname>
      <ethicaddress>11-23 Burwood Rd, Hawthorn, Melbourne, VIC, 3122</ethicaddress>
      <ethicapprovaldate>22/05/2014</ethicapprovaldate>
      <hrec>0013E</hrec>
      <ethicsubmitdate>20/05/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Clinical. 66 McCauley Street, Alexandria, NSW, 2015</address>
      <phone>+61281880311</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Tessa Nikov</name>
      <address>Medlab Clinical. 66 McCauley Street, Alexandria, NSW, 2015</address>
      <phone>+61281880311</phone>
      <fax />
      <email>tessa_nikov@medlab.co</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Clinical. 66 McCauley Street, Alexandria, NSW, 2015</address>
      <phone>+61281880311</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>